Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H46O |
| Molecular Weight | 326.6009 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCCCCCCCCO
InChI
InChIKey=NOPFSRXAKWQILS-UHFFFAOYSA-N
InChI=1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3
DescriptionSources: http://www.drugbank.ca/drugs/DB00632Curator's Comment:: Description was created based on several sources, including
Sources: http://www.drugbank.ca/drugs/DB00632
Curator's Comment:: Description was created based on several sources, including
Docosanol is a saturated 22-carbon aliphatic alcohol which exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol speeds the healing of cold sores and fever blisters on the face or lips. It also relieves the accompanying symptoms, including tingling, pain, burning, and itching. Docosanol works by inhibiting fusion between the human cell plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication. Unlike other cold-sore antivirals, docosanol does not act directly on the virus, and as such it is unlikely it will produce drug resistant mutants of HSV. Used for the topical treatment of recurrent oral-facial herpes simplex episodes (cold sores or fever blisters).
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: HIV-1 replication |
10.0 mM [EC50] | ||
Target ID: P03200 Gene ID: 3783713.0 Gene Symbol: NA Target Organism: Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4) Sources: http://www.drugbank.ca/drugs/DB00632 |
|||
Target ID: CHEMBL2364696 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Abreva Approved UseHerpes Labialis
Topical treatment of recurrent herpes labialis (perioral herpes, cold sores, fever blisters) Launch Date9.6439678E11 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.007 ng × eq/g |
25 mg/kg single, topical dose: 25 mg/kg route of administration: Topical experiment type: SINGLE co-administered: |
DOCOSANOL plasma | Oryctolagus cuniculus population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN |
|
318 ng/mL |
5 g single, oral dose: 5 g route of administration: Oral experiment type: SINGLE co-administered: |
DOCOSANOL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.02 μg × eq × h/g |
25 mg/kg single, topical dose: 25 mg/kg route of administration: Topical experiment type: SINGLE co-administered: |
DOCOSANOL plasma | Oryctolagus cuniculus population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
10 % 5 times / day steady, topical Recommended Dose: 10 %, 5 times / day Route: topical Route: steady Dose: 10 %, 5 times / day Sources: Page: 1 |
unhealthy, 18-77 years n = 370 Health Status: unhealthy Condition: Recurrent herpes simplex labialis Age Group: 18-77 years Sex: M+F Population Size: 370 Sources: Page: 1 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex. | 1991 Dec 1 |
|
| n-Docosanol inhibits in vitro replication of HIV and other retroviruses. | 1996 Jan 1 |
|
| Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial. | 2001 Aug |
|
| Identification of Mycobacterium xenopi by gas chromatography. | 2001 Jan |
|
| The antiviral drug docosanol as a treatment for Kaposi's sarcoma lesions in HIV type 1-infected patients: a pilot clinical study. | 2001 Jan 1 |
|
| Comparison of new topical treatments for herpes labialis: efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection. | 2001 Sep |
|
| Effect of oral Tadenan treatment on rabbit bladder structure and function after partial outlet obstruction. | 2002 May |
|
| Molecular transfer and transport in noncovalent microcontact printing. | 2004 Feb 3 |
|
| Therapeutic options for herpes labialis, II: Topical agents. | 2004 Jul |
|
| Two-dimensional packing patterns of amino acid surfactant and higher alcohols in an aqueous phase and their associated packing parameters. | 2004 May 15 |
|
| Low-dose tadenan protects the rabbit bladder from bilateral ischemia/ reperfusion-induced contractile dysfunction. | 2005 Jan |
|
| [Modern pharmacotherapy of benign prostatic hyperplasia]. | 2005 Nov |
|
| New antiviral agents. | 2006 Apr |
|
| Self-assembled two-dimensional ordered arrays of tripod-type molecules on graphite. | 2006 Jul 4 |
|
| Management of recurrent oral herpes simplex infections. | 2007 Mar |
|
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
| Soybean metabolites regulated in root hairs in response to the symbiotic bacterium Bradyrhizobium japonicum. | 2010 Aug |
|
| A Potent, Broad-Spectrum Antiviral Agent that Targets Viral Membranes. | 2010 May |
|
| Nongenital herpes simplex virus. | 2010 Nov 1 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
D06BB11
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
||
|
WHO-VATC |
QD06BB11
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
||
|
NCI_THESAURUS |
C281
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
661-19-8
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
PRIMARY | |||
|
661-19-8
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
PRIMARY | |||
|
9G1OE216XY
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
PRIMARY | |||
|
M4714
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
PRIMARY | Merck Index | ||
|
DB00632
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
PRIMARY | |||
|
CHEMBL1200453
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
PRIMARY | |||
|
940
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
PRIMARY | |||
|
C47498
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
PRIMARY | |||
|
594680
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
PRIMARY | RxNorm | ||
|
12620
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
PRIMARY | |||
|
5739
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
PRIMARY | |||
|
SUB21986
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
PRIMARY | |||
|
DOCOSANOL
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
PRIMARY | |||
|
211-546-6
Created by
admin on Sat Jun 26 07:15:14 UTC 2021 , Edited by admin on Sat Jun 26 07:15:14 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
